Long-term safety follow-up of patients treated with WU-CART-007 cell therapy
Follows people treated with WU-CART-007 cells for T-cell leukemia or lymphoma for years.
Key facts
- Who runs it
- Allotera Therapeutics
- Where
- Duarte, Los Angeles, Philadelphia, and St Louis, United StatesSee the 4 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
- Status
- Enrolling by invitation
- People taking part
- 44 people, planned
- Started
- 22 Aug 2022
- Expected to end
- 1 Jul 2037
- Type of study
- Observational
- Treatments tested
- Genetic: WU-CART-007
- Record updated
- 20 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received WU-CART-007 in another study. They will be followed for up to 15 years to check for late side effects and survival.
- Age
- 12 years and older
- Sex
- All sexes can join.
- Disease stage
- T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (the conditions listed for the trial). No specific stage is stated.
- Earlier treatment
- Must have received WU-CART-007 in any investigational study.
Where in United States
Also in 1 other country, 1 site
- City of HopeDuarte, United StatesNo longer taking part
- Childrens Hospital LALos Angeles, United StatesNo longer taking part
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part
- Washington UniversitySt Louis, United StatesNo longer taking part
About the trial
What the trial wants to find out
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.
The group in the trial
- Patients treated with WU-CART-007
Patients who received previous treatment with WU-CART-007
Treatment: Genetic: WU-CART-007
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)
- Plain-language title
- Long-term safety follow-up of patients treated with WU-CART-007 cell therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 November 2024